When was BridgeBio founded?

BridgeBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is BridgeBio located?

BridgeBio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California.

Who is the current CEO of BridgeBio?

Neil Kumar of BridgeBio. They have also founded 2 companies and are an angel investors in 1 startup.

How many employees does BridgeBio have?

As of Apr 30, 2026, the latest employee count at BridgeBio is 948.

Is BridgeBio a funded company?

BridgeBio is a funded company, having raised a total of $434M across 5 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Sep 13, 2017.

When was the latest funding round of BridgeBio?

BridgeBio's latest funding was a $***** Post IPO round on Apr 30, 2024, with participation from 11 investors.

What is the annual revenue of BridgeBio?

Annual revenue of BridgeBio is between $500M and $1B as on Dec 31, 2025

Where does BridgeBio rank among its competitors?

BridgeBio ranks 1st amongst 278 active competitors, of which 78 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of BridgeBio?

BridgeBio's top competitors include Alnylam, Alexion and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

BridgeBio - 2026 Company Profile, Team, Funding, Competitors & Financials

BridgeBio is a public company based in Palo Alto (United States), founded in 2015 by Neil Kumar and Frank McCormick. It operates as a Developer of therapeutics for the treatment of genetic diseases. BridgeBio has raised $434M in funding from KKR and Viking Global Investors. The company has 278 active competitors, including 78 funded and 96 that have exited. Its top competitors include companies like Alnylam, Alexion and PTC Therapeutics.

Company Details

Developer of therapeutics for the treatment of genetic diseases. It utilizes a mapping of various genetic disease landscapes to identify opportunities for therapeutic intervention. The company's drug candidates include PTCH1-inhibitor for Gorlin syndrome and S1P-lyase inhibitor for Darier disease and Hailey-Hailey disease and others.

Website: bridgebio.com
Email ID: *****@bridgebio.com
Phone Number: +1 **********
Registered Address: Palo Alto, California

Key Metrics

Founded Year

2015

Location

Palo Alto, United States

Stage

Public

Total Funding

$434M in 5 rounds

Latest Funding Round

Post IPO, Apr 30, 2024, $*****

Investors

KKR & 21 more

Ranked

1^st among 278 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

948 as on Apr 30, 2026

Investment & Acquisitions

Eidos Therapeutics & 3 more

Similar Companies

Alnylam & 312 more

Exit Details

Public

View BridgeBio's full profile

BridgeBio is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BRIDGEBIO SERVICES, INC. CIN: 352592788 , United States, Active	Dec 31, 1999	-	707 (As on Dec 31, 2024)	-
BRIDGEBIO PHARMA LLC CIN: 5984875 , United States, Active		-	576 (As on Dec 31, 2021)	-
BRIDGEBIO PHARMA, INC. CIN: 1743881 , United States, Active	May 16, 2019	$500M - $1B (As on Dec 31, 2025)	-	-

BridgeBio got listed on Jun 27, 2019.

Click here to take a look at BridgeBio's IPO in detail

BridgeBio has raised a total funding of $434M over 5 rounds. Its first funding round was on Sep 13, 2017. Its latest funding round was a Post IPO round on Apr 30, 2024 for $*****. 11 investors participated in its latest round. BridgeBio has 22 institutional investors.

Here is the list of recent funding rounds of BridgeBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2024	1887807	Post IPO	6669807	4751818	2159777	5268851
Feb 23, 2021	7733500	Post IPO	8227535	2986672	3945085	LigaChemBio
Jan 25, 2021	4577402	Post IPO	4336114	4160510	1337492	3551371

Access funding benchmarks and valuations. Sign up today!

View details of BridgeBio's funding rounds and investors

The founders of BridgeBio are Neil Kumar and Frank McCormick. Neil Kumar is the CEO of BridgeBio.

Here are the details of BridgeBio's key team members:

Neil Kumar: Co-Founder & CEO of BridgeBio and founder of 2 other companies, QED and Eidos Therapeutics. They are also an angel investor in 1 startup.
Contact Info: 1 email address
Frank McCormick: Co-Founder of BridgeBio.
Contact Info: 1 email address

View details of BridgeBio's Founder profiles and Board Members

BridgeBio's employee count trend

BridgeBio has 948 employees as of Apr 26. Here is BridgeBio's employee count trend over the years:

Uncover BridgeBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BridgeBio include Alnylam, Alexion and PTC Therapeutics. Here is the list of Top 10 competitors of BridgeBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Deerfield, Athyrium Capital Management & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on BridgeBio's competitors? Click here to see the top ones

BridgeBio has made 3 investments in companies including Eidos Therapeutics and PellePharm. BridgeBio has also acquired 1 companies including Eidos Therapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Oct 05, 2020	Acquisition	Eidos Therapeutics	2016	Palo Alto (United States)
Apr 05, 2018	Investments	Eidos Therapeutics	2016	Palo Alto (United States)
Jul 31, 2017	Investments	PellePharm	2012	Menlo Park (United States)